NO20055143D0 - Doseringsformer innbefattende AG013736 - Google Patents

Doseringsformer innbefattende AG013736

Info

Publication number
NO20055143D0
NO20055143D0 NO20055143A NO20055143A NO20055143D0 NO 20055143 D0 NO20055143 D0 NO 20055143D0 NO 20055143 A NO20055143 A NO 20055143A NO 20055143 A NO20055143 A NO 20055143A NO 20055143 D0 NO20055143 D0 NO 20055143D0
Authority
NO
Norway
Prior art keywords
dosage forms
forms including
dosage
forms
Prior art date
Application number
NO20055143A
Other languages
English (en)
Other versions
NO20055143L (no
Inventor
James Lawrence Freddo
Dana Hu-Lowe
Yazdi Kersi Pithavala
Heidi Marie Steinfeldt
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20055143D0 publication Critical patent/NO20055143D0/no
Publication of NO20055143L publication Critical patent/NO20055143L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055143A 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736 NO20055143L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46069503P 2003-04-03 2003-04-03
US49177103P 2003-07-31 2003-07-31
PCT/IB2004/000867 WO2004087152A1 (en) 2003-04-03 2004-03-17 Dosage forms comprising ag013736

Publications (2)

Publication Number Publication Date
NO20055143D0 true NO20055143D0 (no) 2005-11-02
NO20055143L NO20055143L (no) 2006-01-03

Family

ID=33135143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055143A NO20055143L (no) 2003-04-03 2005-11-02 Doseringsformer innbefattende AG013736

Country Status (16)

Country Link
US (1) US20040224988A1 (no)
EP (1) EP1613320A1 (no)
JP (1) JP2006522087A (no)
KR (1) KR20050119671A (no)
AR (1) AR043822A1 (no)
AU (1) AU2004226586B2 (no)
BR (1) BRPI0409230A (no)
CA (1) CA2520932A1 (no)
MX (1) MXPA05009303A (no)
NL (1) NL1025873C2 (no)
NO (1) NO20055143L (no)
PA (1) PA8599701A1 (no)
RU (2) RU2341263C2 (no)
TW (1) TW200423933A (no)
UY (1) UY28255A1 (no)
WO (1) WO2004087152A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005094830A1 (en) * 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
CN101052633A (zh) * 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
BRPI0518203A2 (pt) * 2004-11-02 2009-03-10 Pfizer mÉtodos para preparaÇço de compostos indazol
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2134702B2 (en) 2007-04-05 2023-08-30 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
CN101801413A (zh) 2007-07-12 2010-08-11 托勒克斯股份有限公司 采用gitr结合分子的联合疗法
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
TW201531309A (zh) 2011-09-30 2015-08-16 Pfizer Ｎ-甲基-２-〔３-（（ｅ）-２-吡啶-２-基-乙烯基）-１ｈ-吲唑-６-基硫烷基〕苯甲醯胺之藥學組成物
CN103917234A (zh) 2011-11-11 2014-07-09 辉瑞大药厂 用于治疗慢性骨髓性白血病的n-甲基-2-〔3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基〕-苯甲酰胺
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
HUE041469T2 (hu) * 2014-02-04 2019-05-28 Pfizer PD-1 antagonista és VEGFR inhibitor kombinációja rák kezelésére
JP6414727B2 (ja) * 2014-04-01 2018-10-31 公益財団法人ヒューマンサイエンス振興財団 関節疾患の治療予防剤
CN104013589A (zh) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 一种阿西替尼口腔崩解片及其制备方法
EP3185866A1 (en) 2014-08-25 2017-07-05 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
AU2016222928B2 (en) 2015-02-26 2021-05-13 Merck Patent Gmbh PD-1 / PD-L1 inhibitors for the treatment of cancer
MY193229A (en) 2015-06-16 2022-09-26 Merck Patent Gmbh Pd-l1 antagonist combination treatments
WO2017139417A1 (en) 2016-02-08 2017-08-17 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
IL315265A (en) 2022-03-03 2024-10-01 Pfizer Inc Multiple antibodies and their uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587458A (en) * 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
CA2372813A1 (en) * 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5339184A (en) * 1992-06-15 1994-08-16 Gte Laboratories Incorporated Fiber optic antenna remoting for multi-sector cell sites
US5459607A (en) * 1993-04-19 1995-10-17 C-Cor/Comlux, Inc. Synchronous optical digital transmission system and method
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
EP0821671B1 (en) * 1995-04-20 2000-12-27 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
JP3588984B2 (ja) * 1997-08-20 2004-11-17 Ｋｄｄｉ株式会社 光パワー計測システム並びにそのための端局及び中継器
GB2332603B (en) * 1997-12-22 2000-07-19 Lsi Logic Corp Improvements relating to multidirectional communication systems
US6529303B1 (en) * 1998-03-05 2003-03-04 Kestrel Solutions, Inc. Optical communications networks utilizing frequency division multiplexing
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6643470B1 (en) * 1999-10-01 2003-11-04 Matsushita Electric Industrial Co., Ltd. FM signal converter, FM signal optical transmitter and FM signal optical receiver

Also Published As

Publication number Publication date
EP1613320A1 (en) 2006-01-11
UY28255A1 (es) 2004-11-30
RU2008122358A (ru) 2009-12-10
US20040224988A1 (en) 2004-11-11
NL1025873C2 (nl) 2006-02-14
AU2004226586A1 (en) 2004-10-14
RU2005128791A (ru) 2006-05-10
AU2004226586B2 (en) 2008-12-11
CA2520932A1 (en) 2004-10-14
AR043822A1 (es) 2005-08-17
KR20050119671A (ko) 2005-12-21
PA8599701A1 (es) 2004-11-26
TW200423933A (en) 2004-11-16
NO20055143L (no) 2006-01-03
MXPA05009303A (es) 2005-10-05
NL1025873A1 (nl) 2004-10-05
WO2004087152A1 (en) 2004-10-14
BRPI0409230A (pt) 2006-03-28
RU2341263C2 (ru) 2008-12-20
JP2006522087A (ja) 2006-09-28

Similar Documents

Publication Publication Date Title
NO20055143D0 (no) Doseringsformer innbefattende AG013736
NO20052914D0 (no) Terapeutiske forbindelser
NO20054682D0 (no) Sikker transdermal doseringsform
IS7689A (is) Fjölþátta lyfjaskammtaform
IS7464A (is) Asíþrómýsín lyfjaskammtaform með minni hliðarverkanir
DE602004017700D1 (de) Transmukosen verabreichung
IS7894A (is) Skammtaform með ofnæmisvaka
IS8108A (is) Ný efnasambönd
DE602004018837D1 (de) Ptidase-iv-inhibitoren
IS8228A (is) Ný asetídínefnasambönd
DE602004006494D1 (de) Trittbrett
DK1587478T3 (da) Farmaceutisk sammensætning
IS8292A (is) Ný efnasambönd
FI20030261A (fi) Iskulaite
NO20050689L (no) Terapeutisk anvendelse
DK1597171T3 (da) Terapeutisk mikroskum
NO20044188L (no) Kontrollerte frigjoringsdoseformer
DE602004022810D1 (de) Mehrdosis-inhalator
NO20034952D0 (no) Farmasöytiske forbindelser
DE602004022100D1 (de) Stimulationshilfe
FI20031158A0 (fi) Inhalaattori
FR2854556B1 (fr) Repose-pied
DOP2003000794A (es) Nuevos compuestos farmaceuticos
SE0302428D0 (sv) Therapeutic heterocycles
FI20030224A0 (fi) Uudet farmaseuttiset käytöt

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application